Delivering Pharmaceutical Innovations Domestically and Globally
Toward Realizing the JPMA's Vision for 2035Our activities are centered on the three pillars of Innovation, Access, and Trust.
Consistently produce innovations to benefit health spans and the economy
Bring innovative new drugs to the public more quickly to enhance health security
Commit to ethical conduct and transparency to foster trust in the pharma industry
-
Public Affairs Committee
JPMA Newsletter [Extra]: JPMA Holds First Town Hall Meeting! is now available.
-
Review Board of Ethical Drug Product Information Brochure Event Report
Workshop for Persons Responsible for Product Information Overview Management and Practical Responsibility for Product Information Overview Management in 2025" was held.
-
Latest JPMA Newsletter JPMA holds its first Town Hall Meeting! Creating the Future Together with the Power of Change and Challenge
-
Event Report: Updated April 16 "2026 Life Science IP Forum" was held.
-
DATA BOOK 2026" is now available.
-
Scientific and Practical Requirements for Drug Candidate Substances for Companies ~Statement of TPP
-
JPMA's Vision for 2035" and "JPMA's Policy Proposals for 2025" released on Feb. 26, 2025
Updates
-
Public Affairs Committee
JPMA Newsletter [Extra]: JPMA Holds First Town Hall Meeting! is now available.
-
Intellectual Property Committee Event Report
Held "2026 Life Science IP Forum
-
Review Board of Ethical Drug Product Information Brochure Event Report
Workshop for Persons Responsible for Product Information Overview Management and Practical Responsibility for Product Information Overview Management in 2025" was held.
-
Drug Evaluation Committee
Results of Questionnaire for Pharmaceutical Companies on Post-Marketing Surveillance" is now available.
-
Drug Evaluation Committee
The following pages are released / "Names of companies that have adopted the common template for Explanatory and Consent Documents (ICF)" (Japanese only)
-
Drug Evaluation Committee
Collection of Examples of Cloud System Introduction at Medical Institutions" has been posted on the "Standard Operating Procedures, etc. for Electromagnetic Handling of Clinical Trial Documents (2024 Edition)" page.
-
News Release Drug Evaluation Committee
3 organizations have produced and released educational materials for the general public on "Don't believe everything you read" in the medical and health fields.
-
Announcement Public Affairs Committee
The JPMA website (top page) has been renewed.
-
Announcement Code Compliance Committee
Revision of Transparency Guideline for the Relation between Corporate Activities and Medical Institutions
-
Announcement
Business Policy, Business Plan, and Implementation Plan" for FY2026 is now available.
-
News Release
Election of New Board Members
-
Announcement
DATA BOOK 2026" is now available.
-
Public Affairs Committee
JPMA Newsletter [Extra]: JPMA Holds First Town Hall Meeting! is now available.
-
Intellectual Property Committee Event Report
Held "2026 Life Science IP Forum
-
Review Board of Ethical Drug Product Information Brochure Event Report
Workshop for Persons Responsible for Product Information Overview Management and Practical Responsibility for Product Information Overview Management in 2025" was held.
-
Drug Evaluation Committee
Results of Questionnaire for Pharmaceutical Companies on Post-Marketing Surveillance" is now available.
-
Drug Evaluation Committee
The following pages are released / "Names of companies that have adopted the common template for Explanatory and Consent Documents (ICF)" (Japanese only)
-
Drug Evaluation Committee
Collection of Examples of Cloud System Introduction at Medical Institutions" has been posted on the "Standard Operating Procedures, etc. for Electromagnetic Handling of Clinical Trial Documents (2024 Edition)" page.
-
Intellectual Property Committee Event Report
Held "2026 Life Science IP Forum
-
Review Board of Ethical Drug Product Information Brochure Event Report
Workshop for Persons Responsible for Product Information Overview Management and Practical Responsibility for Product Information Overview Management in 2025" was held.
-
Public Affairs Committee Event Report
Report on the JPMA Media Forum
-
Pharmaceutical Industrial Policy Committee Event Report
JPMA Rare Disease Day 2026 Symposium" Report Video and Report are now available.
-
International Affairs Committee Event Report
Report on "The 5th Japan-Vietnam Joint Symposium" is now available.
-
Public Affairs Committee Event Report
JPMA Presidents Press Conference" is now available.
About JPMA
Under the JPMA Board of Directors, 12 committees composed of member companies and 6 specialized organizations, including the Office of Pharmaceutical Industry Research (OPIR) which functions as a think tank, carry out a wide range of initiatives. These activities aim to establish a robust drug discovery ecosystem for the development of innovative pharmaceuticals, ensure compliance with regulatory frameworks such as the Pharmaceuticals and Medical Devices Act, and build trust with key stakeholders.
Each committee and specialized body bring together a diverse pool of talent - from young professionals to experienced experts - working across organizational boundaries. Through mutual collaboration and constructive exchange, they advance pharmaceutical innovation, promote the appropriate use of medicines, enhance transparency in distribution, foster international cooperation, and formulate policy proposals. In addition, JPMA conducts various surveys and research projects to address industry-wide challenges. By working closely with government authorities, patient advocacy groups, and other relevant organizations, JPMA supports the sound and sustainable development of the pharmaceutical industry.
JPMA's Vision
Consistently produce innovations to benefit health spans and the economy
- Pharmaceutical innovations
- Leading-edge scientific technology
- Pharmaceutical manufacturing technology
- Domestic manufacturing infrastructure
- Making Japan a science and technology powerhouse
- Fostering highly skilled talent
- PPI/E
- Drug discovery that involves patients and the public
- Co-creation
- Drug discovery ecosystem
- Job creation
- Extending health spans
- Well being
- Pharma as a core industry
- Economic growth
Bring innovative new drugs to the public more quickly to enhance health security
- A social security system that gives patients swift access to “the latest treatments” and stable access to “global-standard treatments”
- Positive investment cycle
- Building an attractive domestic market
- Drug pricing that properly factors in the worth of innovation
- Health security for Japan
Commit to ethical conduct and transparency to foster trust in the pharma industry
- Sustainable Development Goal 3 (Ensure healthy lives and promote well-being for all at all ages)
- Overcome the social challenges raised by Japan’s aging population
- Ethical soundness, code of behavior, and transparency
- Boost public literacy in health and medicine
- Social significance of pharmaceuticals and the pharma industry
- Encourage the public and younger people to enter the pharma industry
- Climate change
- Environmental issues
Member Companies
The JPMA has 68 R&D-oriented JPMA member companies (as of April 1, 2026).
